MDGL Madrigal Pharmaceuticals (MDGL) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001157601
Form 144 · 4
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
224
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · no price filed
What the filings say about MDGL
Insiders, 180 days
-$11.8M net sold
4 sellers · 49% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$32.3M
4 notices
Madrigal Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, MADRIGAL PHARMACEUTICALS, INC. insiders sold a net $11.8M of stock across 717 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 32 earlier Form 4 trades (code P or S) here by this insider (32 sales), the last on Sep 9, 2026.
- The trade is 0.0% of the 202,907 shares held after it.
- 1 other insider sold within 30 days.
- 224 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Sibold William John sold about $32.0K of MDGL under a 10b5-1 plan on Sep 11, 2026; 1 other insider sold within 30 days and 224 funds added in the latest 13F quarter.Context
- 32 earlier Form 4 trades (code P or S) here by this insider (32 sales), the last on Sep 9, 2026.
- The trade is 0.1% of the 202,801 shares held after it.
- 1 other insider sold within 30 days.
- 224 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Sibold William John sold about $56.6K of MDGL under a 10b5-1 plan on Sep 11, 2026; 1 other insider sold within 30 days and 224 funds added in the latest 13F quarter.Context
- 32 earlier Form 4 trades (code P or S) here by this insider (32 sales), the last on Sep 9, 2026.
- The trade is 0.1% of the 202,583 shares held after it.
- 1 other insider sold within 30 days.
- 224 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Sibold William John sold about $116.8K of MDGL under a 10b5-1 plan on Sep 11, 2026; 1 other insider sold within 30 days and 224 funds added in the latest 13F quarter.Context
- 32 earlier Form 4 trades (code P or S) here by this insider (32 sales), the last on Sep 9, 2026.
- The trade is 0.1% of the 202,423 shares held after it.
- 1 other insider sold within 30 days.
- 224 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Sibold William John sold about $86.0K of MDGL under a 10b5-1 plan on Sep 11, 2026; 1 other insider sold within 30 days and 224 funds added in the latest 13F quarter.Context
- 32 earlier Form 4 trades (code P or S) here by this insider (32 sales), the last on Sep 9, 2026.
- The trade is 0.3% of the 201,736 shares held after it.
- 1 other insider sold within 30 days.
- 224 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Sibold William John sold about $371.4K of MDGL under a 10b5-1 plan on Sep 11, 2026; 1 other insider sold within 30 days and 224 funds added in the latest 13F quarter.717 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$11.8M over 180 days
-$6.6M over 90 days
below 86% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
224 funds bought in last quarter
more than 92% of Pharma & Biotech
Revenue
+432.1% year over year
more than 92% of Pharma & Biotech
Margin
-30.1% net margin
more than 55% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
17.5% of the float short (float per yahoo 2026-10-26) · 9.8 days to cover · settled 2026-09-30
more than 73% of Pharma & Biotech
What changed in the last 30 days
Sep 28Director PAUL FRIEDMAN filed to sell $25.8M by Sep 28 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch MDGL
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+4.4%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MDGL: institutional holders (13F)
13F holdings, latest reported quarter
2,143,131 sh
$1.2B
1,993,687 sh
$1.1B
1,936,099 sh
$1.0B
1,833,333 sh
$984.4M
1,340,020 sh
$719.5M
Congress trades in MDGL
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
MDGL planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
PAUL FRIEDMAN
Filed 2026-09-28
$25.8M
WILLIAM SIBOLD
Filed 2026-09-11
$2.8M
William John Sibold
Filed 2026-09-09
$3.4M
Shannon Kelley
Filed 2026-08-20
$337.0K
William Sibold
Filed 2026-07-20
$1.4M
MDGL mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
VALUE LINE LARGER COMPANIES FOCUSED FUND, INC.
$18.8M position · as of 2026-06-30
4.3%
Janus Henderson Transformational Growth ETF
$965.0K position · as of 2026-07-31
3.6%
Artisan Small Cap Fund
$25.3M position · as of 2026-06-30
2.6%
Baron Health Care Fund
$2.4M position · as of 2026-06-30
2.1%
Developing Growth Portfolio
$1.4M position · as of 2026-06-30
1.7%
NYLIM Fiera SMID Growth Fund
$3.3M position · as of 2026-07-31
1.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
14 registered trials, 8 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
4
Phase 1
1 active
4
Phase 2
2 active
4
Phase 3
3 active
1
Phase 4
1 active
1
Not applicable
1 active
What changed recently
Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults Wit
2026-10-17 · Not Yet Recruiting → Recruiting
Phase 4
Resmetirom in Patients With MASH and HFpEF
2026-10-17 · Not Yet Recruiting → Recruiting
Phase 1
Study of Resmetirom in Children and Adolescents With MASH
2026-09-12 · Not Yet Recruiting → Recruiting
Phase 2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Paul A. Friedman.
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2020
$4.5M
$6.5M
$3.7M
+22%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $11.8M sold by insiders over 180 days, 224 funds added last quarter, $32.3M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
MDGL financials
Revenue growth
+432.1%
XBRL, annual
Net margin
-30.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.3B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM MDGL
| FY Dec 2025 | $958.4M |
| FY Dec 2024 | $180.1M |
| FY Dec 2023 | $0 |
| FY Dec 2022 | $0 |
| FY Dec 2021 | $0 |
| Jun 2026 | $364.3M |
| Mar 2026 | $311.3M |
| Dec 2025 | $321.1M |
| Sep 2025 | $287.3M |
| Jun 2025 | $212.8M |
| Mar 2025 | $137.2M |
| Dec 2024 | $103.3M |
| Sep 2024 | $62.2M |
At each fiscal year end
Single quarter
Net margin, TTM
-25.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM MDGL
| FY Dec 2025 | -30.1% |
| FY Dec 2024 | -258.6% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -15.9% |
| Mar 2026 | -30.3% |
| Dec 2025 | -18.2% |
| Sep 2025 | -39.8% |
| Jun 2025 | -19.9% |
| Mar 2025 | -53.4% |
| Dec 2024 | -57.5% |
| Sep 2024 | -172.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$206.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM MDGL
| FY Dec 2025 | -$190.0M |
| FY Dec 2024 | -$457.0M |
| FY Dec 2023 | -$325.7M |
| FY Dec 2022 | -$225.1M |
| FY Dec 2021 | -$184.1M |
| Jun 2026 | $19.1M |
| Mar 2026 | -$171.3M |
| Dec 2025 | -$133.1M |
| Sep 2025 | $79.0M |
| Jun 2025 | -$47.1M |
| Mar 2025 | -$88.9M |
| Dec 2024 | -$104.7M |
| Sep 2024 | -$67.8M |
At each fiscal year end
Single quarter
Debt to equity
0.65x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity MDGL
| FY Dec 2025 | 0.56x |
| FY Dec 2024 | 0.16x |
| FY Dec 2023 | 0.28x |
| FY Dec 2022 | 0.25x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.65x |
| Mar 2026 | 0.63x |
| Dec 2025 | 0.56x |
| Sep 2025 | 0.54x |
| Jun 2025 | 0.17x |
| Mar 2025 | 0.17x |
| Dec 2024 | 0.16x |
| Sep 2024 | 0.15x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.58x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt MDGL
| FY Dec 2025 | -0.56x |
| FY Dec 2024 | -3.87x |
| FY Dec 2023 | -2.81x |
| FY Dec 2022 | -4.56x |
| FY Dec 2021 | n/a |
| Jun 2026 | -0.58x |
| Mar 2026 | -0.79x |
| Dec 2025 | -0.56x |
| Sep 2025 | -0.47x |
| Jun 2025 | -2.60x |
| Mar 2025 | -3.35x |
| Dec 2024 | -3.87x |
| Sep 2024 | -3.68x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-53.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity MDGL
| FY Dec 2025 | -42.5% |
| FY Dec 2024 | -80.3% |
| FY Dec 2023 | -124.0% |
| FY Dec 2022 | -150.1% |
| FY Dec 2021 | -110.9% |
| Jun 2026 | -53.3% |
| Mar 2026 | -49.3% |
| Dec 2025 | -42.5% |
| Sep 2025 | -41.2% |
| Jun 2025 | -36.3% |
| Mar 2025 | -50.2% |
| Dec 2024 | -80.3% |
| Sep 2024 | -129.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-28.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets MDGL
| FY Dec 2025 | -25.0% |
| FY Dec 2024 | -55.4% |
| FY Dec 2023 | -74.5% |
| FY Dec 2022 | -92.9% |
| FY Dec 2021 | -86.3% |
| Jun 2026 | -28.8% |
| Mar 2026 | -27.8% |
| Dec 2025 | -25.0% |
| Sep 2025 | -23.7% |
| Jun 2025 | -26.7% |
| Mar 2025 | -37.7% |
| Dec 2024 | -55.4% |
| Sep 2024 | -79.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital MDGL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-38.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed MDGL
| FY Dec 2025 | -32.9% |
| FY Dec 2024 | -71.4% |
| FY Dec 2023 | -99.0% |
| FY Dec 2022 | -132.5% |
| FY Dec 2021 | -111.0% |
| Jun 2026 | -38.2% |
| Mar 2026 | -36.5% |
| Dec 2025 | -32.9% |
| Sep 2025 | -32.9% |
| Jun 2025 | -34.5% |
| Mar 2025 | -47.3% |
| Dec 2024 | -71.4% |
| Sep 2024 | -106.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing MDGL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$10.1B
market value at close 2026-10-23 on 2026-07-27 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value MDGL
| FY Dec 2025 | $13.4B |
| FY Dec 2024 | $6.7B |
| FY Dec 2023 | $4.6B |
| FY Dec 2022 | $4.7B |
| FY Dec 2021 | $1.4B |
| Jun 2026 | $12.4B |
| Mar 2026 | $12.1B |
| Dec 2025 | $13.4B |
| Sep 2025 | $10.3B |
| Jun 2025 | $6.7B |
| Mar 2025 | $7.2B |
| Dec 2024 | $6.7B |
| Sep 2024 | $4.5B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-2.1%
TTM free cash flow over market value at close 2026-10-23
FCF yield MDGL
| FY Dec 2025 | -1.4% |
| FY Dec 2024 | -6.8% |
| FY Dec 2023 | -7.1% |
| FY Dec 2022 | -4.5% |
| FY Dec 2021 | -12.7% |
| Jun 2026 | -1.7% |
| Mar 2026 | -2.3% |
| Dec 2025 | -1.4% |
| Sep 2025 | -1.6% |
| Jun 2025 | -4.6% |
| Mar 2025 | -5.4% |
| Dec 2024 | -6.8% |
| Sep 2024 | -9.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing MDGL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $958.4M | $180.1M | $0 | $0 |
| Operating income | -$300.1M | -$497.9M | -$380.5M | -$293.6M |
| Net income | -$288.3M | -$465.9M | -$373.6M | -$295.2M |
| EPS (diluted) | -10.15 | -17.31 | -17.33 | -17.23 |
| Operating cash flow | -$189.6M | -$455.6M | -$324.2M | -$224.9M |
| Cash | $198.7M | $100.0M | $99.9M | $331.5M |
| Long-term debt | $339.9M | $117.6M | $115.5M | $49.3M |
SEC XBRL, fiscal years, as known on 2026-10-27
MDGL Stock Sonar score 6/7 axes
Find similar shapesCompareMDGL ranks highest on growth (92nd percentile) and institutional and government (87th), and lowest on insider conviction (9th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MDGL filings, in plain words
Are Madrigal Pharmaceuticals insiders buying or selling MDGL?
In the 180 days to 2026-10-27, Madrigal Pharmaceuticals insiders were net sellers, a net $11.8M across purchases and sales reported on Form 4, by 4 sellers.
Are there planned insider sales of MDGL?
Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $32.3M of stock; the latest, by PAUL FRIEDMAN, was filed 2026-09-28.
Read the full summary
In the 180 days to 2026-10-27, Madrigal Pharmaceuticals insiders were net sellers of MDGL, a net $11.8M across purchases and sales reported on Form 4 by 4 sellers. 49% of the 49 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $32.3M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
